Novel ablation profile shows promise for myopic LASIK

Article

An ongoing European multicentre study is investigating a 'ray-tracing' ablation profile for myopic LASIK using an excimer laser. Results from patients treated by one investigator suggest superior outcomes relative to currently available ablation techniques.

Astudy evaluating outcomes in eyes undergoing LASIK for >-4 D of myopia reaffirms the established efficacy, safety and predictability of treatments performed with the wavefront-optimized (WFO), wavefront-guided (WFG) and topography-guided (T-CAT) ablation profiles of an excimer laser (WaveLight, Alcon Laboratories), and shows interesting promise for further improvement using an investigational 'ray-tracing' (RT) technique, reported Dr Arthur B. Cummings, at the annual meeting of the European Society of Cataract and Refractive Surgeons.

To match the RT study criteria, eyes were retrospectively identified that had been treated for >-4 D of myopia or >-2 D of astigmatism with a spherical equivalent (SE) of >-4 D. Considering eyes with follow-up to at least 3 months, there were 2659 eyes that underwent a WFO treatment, 25 that had T-CAT LASIK, 31 treated with a WFG approach and 57 eyes in the RT study group. Mean SE was highest in the WFO eyes (-6.32 ± 1.74 D) followed by the RT group (-6.08 ± 1.38 D), whereas mean SE was about -5.1 D in both the WFG and T-CAT cohorts.

Developed at the Institute for Refractive and Ophthalmologic Surgery, Zurich, Switzerland, the RT profile integrates data derived from topography, wavefront aberrometry and optical biometry, and performs the final calculations on a virtual model of the patient's eye rather than on the generic Gullstrand model.

The Allegretto WFG treatments were performed using data obtained with a Tscherning aberrometer and the T-CAT treatments used data from either Placido-disc (Topolyzer, WaveLight) or Scheimpflug (Oculyzer, WaveLight) technology. Both the 200-Hz (WaveLight Allegretto) and 400-Hz (WaveLight Allegretto Eye-Q) lasers were used for the treatments although the RT treatments were all performed on the 400-Hz laser.

UCVA at 3 months

Data on UCVA outcomes at 3 months showed about 82% of eyes treated with the RT technique achieved 20/20 or better, which surpassed the rates achieved in the WFO (64%) and T-CAT (58%) groups. All of the WFG eyes achieved 20/20 or better UCVA.

"I perform WFO ablation in the vast majority of patients that present for myopic LASIK of more than -4 D because findings from the FDA study indicated the WFG profile had a benefit only in eyes with higher wavefront error (>0.40 µm higherorder RMS). It was interesting to see there were better results using the WFG technique compared with WFO in this group, although the data need to be interpreted carefully considering the small number of eyes treated by a WFG approach," he emphasized.

"The fact that the T-CAT patients did least well was somewhat surprising because my experience with that protocol has been very positive, although in practice, its major role is as an enhancement technique in complicated, nontreatment-naïve eyes," Dr Cummings affirmed.

Safety outcomes in the three other groups far exceeded the FDA safety criteria that require a <5% rate for loss of 2 or more lines of BCVA. However, 10% of eyes treated with the WFG technique, 9% of eyes in the WFO group and 20% of T-CAT eyes had a 1-line loss of BCVA. Some eyes in each of these groups, albeit a very small percentage, lost 2 or more lines, he said.

Predictability analyses showed about 85% of eyes in all four groups were within 0.5 D of target refraction. Residual astigmatism calculated by vectoral analysis showed the best outcome in the RT group (0.20 ± 0.27 D).

Special contributor Dr Arthur B. Cummings is a consultant ophthalmologist at the Wellington Eye Clinic in Dublin, Ireland. He is an investigator for Alcon/WaveLight and can be reached by E-mail: abc@wellingtoneyeclinic.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.